461432-26-8

Dapagliflozin (BMS-512148) is a selective sodium-glucose co-transporter subtype 2 (SGLT2) inhibitor with antihyperglycemic activity.

Dapagliflozin (Standard) is a reference standard for research and analysis in studies involving Dapagliflozin. Dapagliflozin (BMS-512148) is a glucose co-transporter protein 2 (SGLT2) inhibitor that competitively binds to its target. Dapagliflozin is used in the treatment of type 2 diabetes mellitus and decreases glucose reabsorption in the kidneys and increases urinary excretion of glucose, which results in lowering plasma glucose levels.